Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia

Journal of Infection and Chemotherapy

Volumn 17, Issue 1, 2011, Pages 52-57

  Takesue, Yoshio ^a   Nakajima, Kazuhiko ^a   Takahashi, Yoshiko ^a   Ichiki, Kaori ^a   Ishihara, Mika ^a   Wada, Yasunao ^a   Tsuchida, Toshie ^a   Uchino, Motoi ^a   Ikeuchi, Hiroki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Bacteremia; Methicillin resistant Staphylococcus aureus; Vancomycin

Indexed keywords

HABEKACIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PROGNOSIS; RISK FACTOR;

EID: 79951555045     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0086-0     Document Type: Article

References (16)

1. PA Moise JJ Schentag 2000 Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections Int J Antimicrob Agents 16 Suppl 1 S31 S34 1:CAS:528:DC%2BD3MXnslSrsA%3D%3D 11137406
2. BP Howden PB Ward PG Charles TM Korman A Fuller P du Cros, et al. 2004 Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infect Dis 38 521 528 1:CAS:528:DC%2BD2cXitlyltbY%3D 10.1086/381202 14765345 (Pubitemid 38250962)
3. JI Alos A Garcia-Canas P Garcia-Hierro F Rodriguez-Salvanes 2008 Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage J Antimicrob Chemother 62 773 775 1:CAS:528:DC%2BD1cXhtFCisLfI 10.1093/jac/dkn246 18552338
4. CG Gemmell DI Edwards AP Fraise FK Gould GL Ridgway RE Warren 2006 Guidelines for prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J Antimicrob Chemother 57 589 608 1:CAS:528:DC%2BD28Xis1GltLg%3D 10.1093/jac/dkl017 16507559
5. PA Moise G Sakoulas A Forrest JJ Schentag 2007 Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 51 2582 2586 1:CAS:528:DC%2BD2sXnsVajs7w%3D 10.1128/AAC.00939-06 17452488 (Pubitemid 47047340)
6. G Sakoulas PA Moise-Broder J Schentag A Forrest RC Moellering Jr GM Eliopoulos 2004 Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2398 2402 1:CAS:528:DC%2BD2cXlslamtLY%3D 10.1128/JCM.42.6.2398-2402.2004 15184410 (Pubitemid 38747480)
7. A Soriano F Marco JA Martinez E Pisos M Almela VP Dimova, et al. 2008 Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 193 200 1:CAS:528:DC%2BD1cXhvVClsbk%3D 10.1086/524667 18171250 (Pubitemid 351269157)
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standards. 9th ed. M2-M9. Wayne: Clinical and Laboratory Standards Institute; 2006.
9. TR Walsh A Bolmstrom A Qwarnstrom P Ho M Wootton RA Howe, et al. 2001 Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides J Clin Microbiol 39 2439 2444 1:CAS:528:DC%2BD3MXlsFSjsr8%3D 10.1128/JCM.39.7.2439-2444.2001 11427551 (Pubitemid 32606216)
10. G Steinkraus R White L Friedrich 2007 Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 J Antimicrob Chemother 60 788 794 1:CAS:528:DC%2BD2sXht1ygtbjM 10.1093/jac/dkm258 17623693 (Pubitemid 47434257)
11. HS Sader PD Fey DN Fish AP Limaye G Pankey J Rahal, et al. 2009 Evaluation of vancomycin and daptomycin potency trends ("MIC creep") against methicillin-resistant Staphylococcus aureus collected in nine United States medical centers over five years (2002-2006) Antimicrob Agents Chemother 53 4127 4132 1:CAS:528:DC%2BD1MXht1Kkur%2FF 10.1128/AAC.00616-09 19635961
12. G Sakoulas RC Moellering Jr 2008 Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains Clin Infect Dis 46 S360 S367 1:CAS:528:DC%2BD1cXnsFKqt7w%3D 10.1086/533592 18462091 (Pubitemid 351717323)
13. PA Moise DS Smyth N EI-Fawal D Robinson PN Holden A Forrest, et al. 2008 Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteremia J Antimicrob Chemother 61 85 90 1:CAS:528:DC%2BD1cXhtFWgtw%3D%3D 10.1093/jac/dkm445 18042628
14. L Cui H Murakami K Kuwahara-Arai H Hanaki K Hiramatsu 2000 Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50 Antimicrob Agents Chemother 44 2276 2285 1:CAS:528:DC%2BD3cXmtFylsLo%3D 10.1128/AAC.44.9.2276- 2285.2000 10952568 (Pubitemid 30650868)
15. IL Camargo HM Neoh L Cui K Hiramatsu 2008 Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype Antimicrob Agents Chemother 52 4289 4299 1:CAS:528:DC%2BD1cXhsV2murfM 10.1128/AAC.00417-08 18824611
16. K Mitsutaka Y Tajima T Ito Y Yamashiro K Hiramatsu 2009 Use of a sensitive chemiluminescence-based assay to evaluate the metabolic suppression activity of linezolid on methicillin-resistant Staphylococcus aureus showing reduced susceptibility to vancomycin J Microbiol Biotechnol 19 734 741 1:CAS:528:DC%2BD1MXhtV2ju7%2FE